Thermo Fisher Scientific (TMO)
(Delayed Data from NYSE)
$596.92 USD
+3.13 (0.53%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $596.52 -0.40 (-0.07%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth D Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$596.92 USD
+3.13 (0.53%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $596.52 -0.40 (-0.07%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth D Momentum D VGM
Zacks News
Thermo Fisher Scientific (TMO) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Thermo Fisher Scientific (TMO) closed the most recent trading day at $620.40, moving +0.3% from the previous trading session.
Hologic's (HOLX) GAI Program to Include Aptima SARS-CoV-2 Assay
by Zacks Equity Research
The addition of Aptima SARS-CoV-2 assay to Hologic's (HOLX) Global Access Initiative is likely to improve its accessibility.
Here's Why You Should Retain Stryker (SYK) Stock Right Now
by Zacks Equity Research
Stryker (SYK) continues to benefit from strength in the robotic-arm assisted surgery platform, Mako, and broad product portfolio. However, pricing pressure remains a concern.
PacBio (PACB) Ties Up to Boost Rare Disease Diagnosis in Canada
by Zacks Equity Research
PacBio's (PACB) recent partnership with Care4Rare, with regard to a study, has the potential to enhance rare disease diagnosis within Canada.
4 Stocks to Watch Out For as MedTech Rides on Buyout Frenzy
by Debanjana Dey
Here are some MedTech stocks - Quidel (QDEL), Thermo Fisher (TMO), Baxter (BAX) and BD (BDX) - that have been quite active in the acquisition front and therefore worth investor attention.
STERIS (STE) Hits a New 52-Week High: What's Driving It?
by Zacks Equity Research
Strong segmental performances are driving the top line for STERIS (STE).
3 Reasons to Retain Integer Holdings (ITGR) Stock For Now
by Zacks Equity Research
Investors continue to be optimistic about Integer Holdings (ITGR) owing to its improving non-medical sales and solid foothold in the broader MedTech space.
Here's Why You Should Retain Cardinal Health (CAH) Stock Now
by Zacks Equity Research
Cardinal Health (CAH) continues to gain traction from the solid pharmaceutical segment and diversified product portfolio. However, contraction in gross margin is a woe.
Nevro's (NVRO) 10 kHz Therapy for Treatment of PDN Gets Coverage
by Zacks Equity Research
Nevro (NVRO) receives coverage for its high-frequency 10 kHz therapy for the treatment of PDN.
Here's Why You Should Hold on to Bruker (BRKR) Stock for Now
by Zacks Equity Research
Investors are optimistic about Bruker's (BRKR) growth in the BioSpin Group and CALID Group.
Here's Why You Should Retain Phibro (PAHC) Stock for Now
by Zacks Equity Research
Investors are optimistic about Phibro (PAHC), given robust performance by its nutritional specialties and vaccine product lines.
Illumina (ILMN) Ties Up With Syapse to Evaluate Biomarker Testing
by Zacks Equity Research
Illumina's (ILMN) recent collaboration will explore the real-world uptake and actionability of comprehensive genomic profiling in patients with advanced cancer.
Omnicell (OMCL) to Expand EnlivenHealth Division With New Buyout
by Zacks Equity Research
Omnicell's (OMCL) $82-million buyout of MarkeTouch Media is likely to expand its Advanced Services portfolio.
Zacks.com featured highlights include: Toll Brothers, Microsoft, Avery Dennison, J.B. Hunt, and Thermo Fisher
by Zacks Equity Research
Zacks.com featured highlights include: Toll Brothers, Microsoft, Avery Dennison, J.B. Hunt, and Thermo Fisher.
Here's Why You Should Retain LHC Group (LHCG) Stock Now
by Zacks Equity Research
LHC Group (LHCG) continues to benefit from strategic deals and a broad array of services.
5 Unbeatable Dividend Growth Stocks for 2022
by Sweta Killa
Beat the market with dividend stocks like Toll Brothers (TOL), Microsoft (MSFT), Avery Dennison (AVY), J.B. Hunt (JBHT) and Thermo Fisher (TMO) in 2022.
The Zacks Analyst Blog Highlights: Thermo Fisher Scientific Inc., QIAGEN N.V. Quest Diagnostics and Quidel Corp.
by Zacks Equity Research
Thermo Fisher Scientific Inc., QIAGEN N.V. Quest Diagnostics,and Quidel Corp. are highlighted in this analyst blog.
Here's Why You Should Add Omnicell (OMCL) Stock for Now
by Zacks Equity Research
Investors are optimistic about Omnicell (OMCL) on strength in medication management and adherence automation solutions.
3 Reasons to Add Accuray (ARAY) Stock to Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Accuray (ARAY) owing to its slew of software upgrades.
Here's Why You Should Hold on to NextGen (NXGN) Stock Now
by Zacks Equity Research
NextGen (NXGN) continues to gain momentum on the back of solid demand for its solutions and strength in EHR. Intense competition is a headwind.
3 Diagnostics Stocks in Focus Amid the Omicron Outbreak
by Riya Anand
Stocks like Thermo Fisher (TMO), QIAGEN (QGEN) and Quidel (QDEL) are expected to gain from increasing testing demand.
Here's Why You Should Hold on to Globus Medical (GMED) for Now
by Zacks Equity Research
Investors are optimistic about Globus Medical (GMED), backed by strength in the Enabling Technologies arm and ExcelsiusGPS platforms.
Thermo Fisher Scientific (TMO) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Thermo Fisher Scientific (TMO) closed the most recent trading day at $667.24, moving +0.27% from the previous trading session.
3 Reasons to Add McKesson (MCK) Stock to Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about McKesson (MCK) owing to its robust Biologics business.
Thermo Fisher (TMO) Hits a 52-Week High: What's Driving It?
by Zacks Equity Research
Strength in end markets and significant contribution from COVID-response related revenues are driving Thermo Fisher's (TMO) top line.